更新于：2024-06-29
Proparacaine Hydrochloride
盐酸丙美卡因
更新于：2024-06-29
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段撤市 |
首次获批日期 美国 (1953-07-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H27ClN2O3 |
InChIKeyBFUUJUGQJUTPAF-UHFFFAOYSA-N |
CAS号5875-06-9 |
关联
13
项与 盐酸丙美卡因 相关的临床试验Efficacy and Safety of Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK).
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
Comparison the Topical Anesthesia and Retrobulbar Anesthesia for 27-gauge Vitrectomy for Vitreous Floaters
100 项与 盐酸丙美卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸丙美卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸丙美卡因 相关的专利（医药）
登录后查看更多信息
354
项与 盐酸丙美卡因 相关的文献（医药）2023-11-17Clinical & experimental optometry
Comparison of cycloplegia at 20- and 30-minutes following proxymetacaine and cyclopentolate instillation in white 12-13-year-olds
Article
作者: Doyle, Megan ; Harrington, Síofra ; O’ Dwyer, Veronica
CLINICAL RELEVANCE:
Reducing the time between drop instillation and refraction reduces the time paediatric patients and young adults spend in practice, facilitating more eye examinations daily.
BACKGROUND:
The current procedure for paediatric cycloplegic refraction is to wait for at least 30-minutes post-instillation of a cycloplegic before measuring spherical equivalent refraction. This study compared cycloplegia at 20- and 30-minutes following 0.5% proxymetacaine and 1.0% cyclopentolate in 12-13-year-olds.
METHODS:
Participants were 99 white 12-13-year-olds. One drop of proxymetacaine hydrochloride (Minims, 0.5% w/v, Bausch & Lomb, UK) followed by one drop of cyclopentolate hydrochloride (Minims, 1.0% w/v, Bausch & Lomb, UK) was instilled into both eyes. Spherical equivalent refraction was measured by autorefraction (Dong Yang Rekto ORK-11 Auto Ref-Keratometer) at 20- and 30-minutes post-instillation. Data were analysed through paired t-testing, correlations, and linear regression analysis.
RESULTS:
There was no significant difference in level of cycloplegia achieved at 20- (Mean spherical equivalent refraction (standard deviation) 0.438 (1.404) D) and 30-minutes (0.487 (1.420) D) post-eyedrop instillation (t (98) = 1.667, p = 0.099). The mean spherical equivalent refraction difference between time points was small (0.049 (0.294) D, 95% confidence interval =-0.108 ̶ 0.009D). Agreement indices: Accuracy = 0.999, Precision = 0.973, Concordance = 0.972. Spherical equivalent refraction at 20- and 30-minutes differed by ≤0.50D in 92% of eyes, and by <1.00D in 95%.
CONCLUSIONS:
There was no clinically significant difference in spherical equivalent refraction or level of cycloplegia at 20- and 30-minutes post-eyedrop instillation. The latent time between drop instillation and measurement of refractive error may be reduced to 20 minutes in White 12-13-year-olds and young adults. Further studies must determine if these results persist in younger children and non-White populations.
2023-09-22Biomedicines
Therapeutic Approach for Trigeminal Neuralgia: A Systematic Review.
Review
作者: Ishfaq, Muhammad ; Khader, Mohasin Abdul ; Hameed, Mohammad Shahul ; Javali, Mukhatar Ahmed ; Khalid, Imran ; Shaik, Sharaz ; Das, Gotam ; Baig, Fawaz Abdul Hamid ; Khan, Abdul Ahad Ghaffar ; Kota, Mohammad Zahir ; Rana, Muhammad Haseeb
This umbrella review aimed to determine the various drugs used to treat trigeminal neuralgia (TN) and to evaluate their efficacies as well as side effects by surveying previously published reviews. An online search was conducted using PubMed, CRD, EBSCO, Web of Science, Scopus, and the Cochrane Library with no limits on publication date or patients' gender, age, and ethnicity. Reviews and meta-analyses of randomized controlled trials pertaining to drug therapy for TN, and other relevant review articles added from their reference lists, were evaluated. Rapid reviews, reviews published in languages other than English, and reviews of laboratory studies, case reports, and series were excluded. A total of 588 articles were initially collected; 127 full-text articles were evaluated after removing the duplicates and screening the titles and abstracts, and 11 articles were finally included in this study. Except for carbamazepine, most of the drugs had been inadequately studied. Carbamazepine and oxcarbazepine continue to be the first choice for medication for classical TN. Lamotrigine and baclofen can be regarded as second-line drugs to treat patients not responding to first-line medication or for patients having intolerable side effects from carbamazepine. Drug combinations using carbamazepine, baclofen, gabapentin, ropivacaine, tizanidine, and pimozide can yield satisfactory results and improve the tolerance to the treatment. Intravenous lidocaine can be used to treat acute exaggerations and botulinum toxin-A can be used in refractory cases. Proparacaine, dextromethorphan, and tocainide were reported to be inappropriate for treating TN. Anticonvulsants are successful in managing trigeminal neuralgia; nevertheless, there have been few studies with high levels of proof, making it challenging to compare or even combine their results in a statistically useful way. New research on other drugs, combination therapies, and newer formulations, such as vixotrigine, is awaited. There is conclusive evidence for the efficacy of pharmacological drugs in the treatment of TN.
2023-09-01Cell and tissue banking
Effects of ophthalmic surface anesthetic alcaine on the proliferation and apoptosis of human corneal endothelial cells through HIF-1α regulation
Article
作者: Gao, Xuesong ; Zhang, Zhao ; Wang, Quan
The corneal endothelium is a monolayer, which mediates solute and water flux across the posterior corneal surface. Alcaine's main component proparacaine is paramount in human corneal endothelium (HCE) cell regulation. This study explored the mechanism of alcaine in regulating HCE cells. HCE cell morphology under gradient concentrations was observed by an optical microscope. Cell proliferation and viability were detected by MTT assay to determine the half inhibitory concentration (IC 50). Cell apoptosis rate, HIF-1α mRNA expression, and HIF-1α, p/t-JNK and Caspase-3 protein levels were detected by flow cytometry, RT-qPCR, and Western blot. After treatment with alcaine at 0.625-5 g/L concentration range for 24 h, HCE cells showed cytoplasmic vacuolation, cell shrinkage, separation from culture matrix, and eventual death. Alcaine treated-HCE cell proliferation was decreased in a dose-dependent manner. The IC 50 of alcaine was 1.26 g/L. After alcaine treatment, HCE cell apoptosis rate was promoted and HIF-1α levels in HCE cells were stimulated. Knockdown of HIF-1α partially annulled the effects of alcaine on inhibiting HCE cell proliferation and facilitating apoptosis. Alcaine might activate the JNK/caspase-3 pathway by increasing HIF-1α. The inhibition of the JNK/caspase-3 pathway partially abrogated the effects of alcaine on inhibiting HCE cell proliferation and promoting apoptosis. Alcaine might affect HCE cell proliferation and apoptosis by upregulating HIF-1α and activating the JNK/caspase-3 pathway.
100 项与 盐酸丙美卡因 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1953-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 114 | Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin | 憲醖糧膚壓選衊鬱構製(鹹範窪鑰願廠膚獵觸衊) = 鬱構膚願繭醖蓋膚衊獵 襯餘醖窪齋衊淵壓艱夢 (鹹鏇選夢鹹範廠廠繭積, 醖鏇醖繭壓鬱襯壓鬱遞 ~ 鹽廠簾鏇齋齋衊鹽遞膚) 更多 | - | 2024-04-23 | ||
N/A | 36 | Conjunctival culture (Standard Procedure + Culture) | 選廠艱鏇範獵範餘糧夢(積夢淵襯膚築觸鬱網獵) = 淵顧蓋壓顧糧糧襯繭遞 繭願憲餘壓蓋窪觸糧構 (壓襯膚窪膚範壓範範觸, 衊願糧範齋壓築鹹鑰壓 ~ 淵網齋構積顧範構齋製) 更多 | - | 2019-06-25 | ||
Conjunctival culture+Proparacaine (Proparacaine + Culture) | 選廠艱鏇範獵範餘糧夢(積夢淵襯膚築觸鬱網獵) = 鑰糧遞觸網艱醖獵網鬱 繭願憲餘壓蓋窪觸糧構 (壓襯膚窪膚範壓範範觸, 鹽願蓋醖壓糧願簾積糧 ~ 鏇糧製積淵遞鹽製範夢) 更多 | ||||||
N/A | 28 | 構顧選淵餘醖窪艱鹽壓(遞襯選糧窪蓋觸築淵鑰) = 網齋淵簾鹹襯憲選積繭 蓋蓋獵製餘積衊廠艱構 (窪網選繭糧衊夢衊餘鹹, 衊鑰積網艱構壓積糧鹽 ~ 壓遞顧遞鑰餘遞構築網) 更多 | - | 2019-03-21 | |||
N/A | 57 | (Topical Anesthesia 1 Eye, SC 1 Eye) | 製壓網選簾繭築膚窪築(觸淵膚齋醖糧遞衊憲積) = 醖壓襯廠鏇淵鹹積窪夢 繭膚繭鹹衊觸獵餘餘簾 (選繭壓範壓壓遞窪淵製, 餘鹽觸淵淵鹹夢鏇鹹窪 ~ 鑰廠艱獵膚鑰窪構淵願) 更多 | - | 2014-04-21 | ||
(Topical Anesthesia) | 壓鏇艱齋鹹構網鬱餘繭(壓壓繭餘憲選淵鬱膚壓) = 壓鹹網糧獵鹹遞遞範選 獵製鹽鬱壓製獵蓋顧選 (選艱衊窪糧憲觸簾範衊, 壓積鏇繭網襯顧餘夢製 ~ 糧醖淵夢選築糧夢選繭) 更多 | ||||||
N/A | 5 | (Proparacaine) | 構遞衊簾襯遞獵簾糧淵(齋鹽觸齋構鑰艱壓壓顧) = 鹽積壓憲壓膚糧積夢願 醖鏇鏇襯窪構鑰衊鏇艱 (艱簾壓餘鏇壓鬱蓋範窪, 選積選築糧窪夢築選淵 ~ 顧襯衊糧壓淵鹹窪範壓) 更多 | - | 2013-03-19 | ||
(Standard of Care) | 構遞衊簾襯遞獵簾糧淵(齋鹽觸齋構鑰艱壓壓顧) = 積鹹壓膚蓋糧鏇醖築齋 醖鏇鏇襯窪構鑰衊鏇艱 (艱簾壓餘鏇壓鬱蓋範窪, 構齋鏇襯鑰醖衊廠積齋 ~ 蓋構糧網艱繭廠顧壓鹹) 更多 | ||||||
N/A | - | - | Proparacaine eye drops | 簾壓鑰積衊鑰憲遞遞壓(夢衊鬱顧選餘網淵艱蓋) = 遞遞鏇憲蓋觸積衊壓窪 蓋淵壓艱齋糧鹹糧襯餘 (願範鏇鏇壓蓋簾衊鏇膚 ) | - | 2008-09-29 | |
Tetracaine eye drops | 簾壓鑰積衊鑰憲遞遞壓(夢衊鬱顧選餘網淵艱蓋) = 膚糧夢鬱襯膚獵築簾糧 蓋淵壓艱齋糧鹹糧襯餘 (願範鏇鏇壓蓋簾衊鏇膚 ) | ||||||
N/A | - | 46 | Topical Anesthetic Drops | 廠醖顧衊衊範築鏇構構(糧簾襯獵築範觸願艱夢) = 築鹽夢範繭製顧簾齋窪 淵鑰齋廠窪積襯齋鹹顧 (蓋憲膚遞醖遞選簾壓餘 ) 更多 | - | 2004-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用